Is this something you ordered, or was it
delivered via BTGC? If the latter, I'm a street-name
shareholder, so it sometimes takes a while to get things
forwarded via my broker.
If the former, I'd be
interested in any synopsis you may care to post, or if you
think it's really worthwhile, I might want to order it
This isthe story that appeared in late December
1999. It clearly states the 4th quarter will be a loss.
Total earnings for year around 26 cents a share.
Already earned about 29. Therefore a loss of a few cents
in the cards for the 4th quarter.
N.J.--(BUSINESS WIRE)--Dec. 29, 1999--Bio-Technology General
(NASDAQ:BTGC - news) today commented that it anticipates full
year 1999 revenues of
approximately $84 million
compared to $77 million in 1998. Despite the growth in
earnings for the year are expected to be between $0.08 and
$0.11 lower than the 1998 EPS of
Company's revenue growth and EPS were adversely impacted by
announced reduction of Oxandrin�
inventory, amounting to more than $15 million, by
Company's distributor for the product, Olsten Health
Services, Inc. Additional contract revenues
strategic alliances anticipated to be concluded by the end
of the fourth quarter were
expected to cover much
of the Oxandrin inventory-related shortfall. While
not yet concluded, the
Company is continuing to
pursue these new relationships.
In commenting on
the anticipated results, Sim Fass, Chairman and CEO
of Bio-Technology General
Corp., stated: ``The
1999 results essentially reflect the impact of what we
believe to be a temporary
situation. With Oxandrin prescriptions up by 28% in the
first eleven months of
1999 compared to the first
eleven months of 1998, and end user sales for the full
expected to be up by 24%, our Oxandrin
business continues to demonstrate robust growth.
should translate into a significant increase in Oxandrin
sales to our distributor in 2000 as both
absorption of the excess inventory is completed, and sales
to Olsten fully reflect the growing end
sales. Moreover, we anticipate further development of
the commercial potential for Oxandrin,
accomplished by an increase in the size of the Company's sales
force and expansion of sales
activity into the wound
Dr. Fass added: ``Several new
key strategic alliances, some of which were expected
contract revenues in the fourth
quarter of 1999, are in the process of advanced
look forward to their consummation in 2000,
and we remain very confident that 2000 will be
record year for BTG in terms of revenues, product sales,
and earnings. We have every expectation
the inventory reduction completed and the current
growth rate of our product sales, we will
be able to
deliver on our commitment of accelerated growth in
Bio-Technology General Corp., a leading
biopharmaceutical company, develops, manufactures and
genetically engineered and other products for human health
care. The Company's products
are marketed in over
thirty countries worldwide.
Statements in this
news release concerning the Company's business outlook
or future economic
profitability, revenues, expenses or other financial items; and
concerning assumptions made or expectations as to any future
events, conditions, performance or
other matters, are
``forward-looking statements'' as that term is defined under the
Laws. Forward-looking statements
are subject to risks, uncertainties and other factors
cause actual results to differ
materially from those stated in such statements. Such risks,
and factors include, but are not limited to, changes
and delays in product development plans
schedules, customer acceptance of new products, changes in
pricing or other actions by
competitors, patents owned
by the Company and its competitors, and general
as well as other risks detailed in
the Company's filings with the Securities and
Draxis Health Starts Phase III Fibrimage
MISSISSAUGA, Ont. -- Draxis Health Inc. (DRAX)
said its Draximage Inc. radiopharmaceutical subsidiary
has started Phase III
clinical trials in Canada
for Fibrimage, a diagnostic tool for deep vein
thrombosis, or DVT.
In a news release, the drug company
said the trial should involve 130 patients and be
completed by the end of the year.
DVTs are blood clots
that form in the lower limbs and can lead to a
pulmonary embolism, or a blockage of blood flow to the
condition that kills about 200,000 people a
year in the U.S., it said.
It said Fibrimage is
based on Fibrin Binding Domain, a recombinant
polypeptide developed by Bio-Technology General Corp.
(BTGC) and licensed to Draximage on an exclusive,
BTGC never posts Q4 numbers .. rather they just
post 12 month totals ... forcing you or i to back out
the cumulative numbers from Q3 to get the respective
revs, EPS, etc. in Q4 ... never understood why they do
You must have a pretty high opinion of
I'd say riding this piece of s---- for 3 yrs at no
gain is long enough. The 3 yrs stagnation speaks for
itself regardless of the investor. Everyone's investment
scenario/objectives/methods are different. If I'm so stupid and irresponsible
then how'd I manage a 1300 % gain in my net position
over the last 15 months?
The earnings were what they projected. At this
point too much emphasis is being placed on EPS. What I
want to see is higher sales and R&D
If I am going to invest in biotech I am not looking
to double my money, I am looking for a 10 fold
increase (at least). This is a young company with the
original management running it. As BTG grows, more
professional and Sophisticated employees will be hired that
know how to rum a public company. For instance,
established companies know when their auditors will sign off
because there is an agreed upon date. Everyone knows what
the date is.
In regards to share price
potential, right now biotech is loved which helps the price.
BTG is relatively cheap compared to other pharm.
companies. If the gap increases regardless of the "posion
pill" BTG will be gobbled up. The fact that they are
based in NJ helps since so many major Pharm. co's are
in NJ. R&D lab based in Isreal a big +. There is a
lot of talent out there.
BTG pipeline is
extended out quite far into 2000's. But if they can market
better what they already have sales would rise. Any
larger company could do a better job.
on a lot of cash but they do not know how to spend
it. They may have missed the opportunity to buy cheap
biotech companies or late stage drugs. At this point they
should forget about earnings and step up the pace in
I think that DNA will not be able to appeal (my
wish) because of all the bad press surrounding HGH.
This could prove to be a real positive even though DNA
has a lock on the market.
If you are looking
for great earnings and a pop in price in 2000 I would
Good luck to all longs!
I don't mean to get you mad. I have
owned this stock since the David Blech
When I say BTG is a young company I am comparing BTG
to companies in general, not necessarily to biotech
I am not "bad mouthing" the company but they have
made missteps in announcing their intentions as if
they were imminent.
With that said I think BTG
has a lot of potential. I do not mind your opinion, I
hope you can respect mine.
Sheesh, I hope you realize how many graves you
set to spinning with that idea. :-)
apologize if I was one of those who ripped into you way
back when. I follow too many boards to remember which
posters I've rubbed the wrong way or which I've
befriended. stock_it_to_me_2000 may hold a grudge but I'll
likely forget about this set to by the time I wake up
There's a fellow on LIFC who apparently
shorted it several times, but he just said he was out
when it recently started moving up again. That's what
keeps me from trying my hand at it... the fear that the
stock so close to announcing profitability (or a j/v or
FDA approval) wouldn't come back down.
to a profitable week.
You must be on cloud 9 with IDX ... followed it a
few years ago ... had a good run back in '95 then a
roller coaster the past few years ... almost a double
this month alone ... now if MLOG can move ... i see
you apparently are in that too, as it am (at 1 3/16)
Your "4 months ago" date sorta threw me. I agree
that Mgmt's past perfomance has left questions of
credibility, but they seem a little more appreciative of being
able to follow up on promises. I didn't develop any
anticipation of particulars from that press release, other
"some good things are in the works". I'm also not
reading much into "several" new key strategic alliances.
Right now, the only things I'm looking for imminently
are the annoucement of a marketing alliance for
BioHepB, and a strategy for marketing HGH in US (unless
DNA is successful in blocking that
I'm certainly open to pleasant surprises if anything
else pops in the short-term. I do think that for 2000,
BTG really needs to meet, and hopefully slightly beat
earnings estimates, and also to make something "new"
happen in the form of selling the Hep B vaccine and/or
establishing a foothold in the HGH market (no matter how
small) in US.
i'm amazed at those who take shots at you ... at
least you post value added information ... and bozos
like stock_it_to_me_2000 seem to have a chip on their
shoulder or have a real "nned" to talk in a condescending
manner ... of course i recall when a few people ripped
into me when i thought BTGC was a good short way back
when ... and even though i was long i will on occasion
play the short side (short term) ... but man, do
people have a need to rant and rave when someone doesn't
see things as they do ...